Johnson & Johnson – Page 2

Pharmaceutical Giants J&J, Bayer, and Pfizer Announce Layoffs Affecting Nearly 500 Employees

10 months ago talkbio0Tagged Bayer, Biotech Layoffs, Drug Industry, Johnson & Johnson, layoffs, Pfizer

Layoffs, Pharmaceutical Industry, Johnson & Johnson, Bayer, Pfizer, Biotech Layoffs, Workforce Reduction

Big Pharma’s Layoff Wave Continues in New Jersey: J&J and Bayer Announce Significant Job Cuts

10 months ago talkbio0Tagged Bayer, Big Pharma layoffs, Drug Industry, Johnson & Johnson, New Jersey, restructuring

Big Pharma layoffs, New Jersey, Johnson & Johnson, Bayer, pharmaceutical industry restructuring

J&J and Legend’s Carvykti Demonstrates Significant Survival Benefit in Earlier-Line Multiple Myeloma Treatment

10 months ago talkbio0Tagged Benefit, CAR-T, CARTITUDE-4, Carvykti, Continuance of life, Johnson & Johnson, Legend Biotech, Multiple Myeloma, second-line

Carvykti, multiple myeloma, CAR-T therapy, Johnson & Johnson, Legend Biotech, CARTITUDE-4, survival benefit, second-line treatment

SpectraWAVE Secures $50M Series B Funding Led by J&J to Enhance Intravascular Imaging System

11 months ago talkbio0Tagged Coronary Arteriosclerosis, HyperVue Imaging System, Intravascular imaging, Johnson & Johnson, Medical Imaging, Series, SpectraWAVE

SpectraWAVE, Johnson & Johnson, intravascular imaging, HyperVue Imaging System, coronary artery disease, medical imaging, Series B funding

Federal Agency Rejects J&J’s 340B Rebate Model, Vows to Take Action

11 months ago talkbio0Tagged Contact Role - Federal Agency, Gegenhalten, Health care facility, Johnson & Johnson, Policy, Programs - Publication Format, Rebate Model

340B Program, Johnson & Johnson, Rebate Model, Federal Agency Opposition, Healthcare Policy

J&J’s Rybrevant Combination Approved for First-Line Treatment of EGFR-Mutated Non-Small Cell Lung Cancer

11 months ago talkbio0Tagged Approved, chemotherapy-free regimen, Epidermal Growth Factor Receptor, Johnson & Johnson, lazertinib, Mutation, Non-Small Cell Lung Carcinoma, Rybrevant, United States Food and Drug Administration

Rybrevant, Johnson & Johnson, FDA approval, non-small cell lung cancer, EGFR mutations, lazertinib, chemotherapy-free regimen

FDA Approves Johnson & Johnson’s New Multiple Myeloma Therapy

12 months ago talkbio0Tagged Antibodies, Bispecific, Approved, CAR-T, Carvykti, Cell Therapy, DARALEXASPRO, Johnson & Johnson, Multiple Myeloma, TALVEY, United States Food and Drug Administration

FDA approval, Johnson & Johnson, multiple myeloma, CAR-T cell therapy, bispecific antibody, TALVEY, CARVYKTI, DARALEXASPRO

J&J Abandons Addex-Partnered Epilepsy Candidate After Phase II Failure

1 year ago talkbio0Tagged Epilepsy, Johnson & Johnson, nervous system disorder, Phase 2 Clinical Trials, Receptors, Metabotropic Glutamate

Addex Therapeutics, Johnson & Johnson, ADX71149, Epilepsy, Phase II Trial, Metabotropic Glutamate Receptor, Neurological Disorders

Pfizer, Bristol Myers Squibb, and Johnson & Johnson: Navigating the Looming Patent Cliff

1 year ago talkbio0Tagged Acquisitions, Biological Factors, Biosimilars, Drug Industry, Johnson & Johnson, mergers, Myers, Patent Cliff, patent expirations, Pfizer, Revenue Loss, squibb

Patent Cliff, Pharmaceutical Industry, Pfizer, Bristol Myers Squibb, Johnson & Johnson, Patent Expirations, Biologics, Biosimilars, Revenue Loss, Mergers and Acquisitions

J&J’s Tremfya Fails to Meet Primary Endpoint in Giant Cell Arteritis Trial

1 year ago talkbio0Tagged Giant Cell Arteritis, glucocorticoid-free remission, Johnson & Johnson, Phase 2 Clinical Trials, Primary Endpoint, Tremfya

Tremfya, Johnson & Johnson, Giant Cell Arteritis, Phase II Trial, Primary Endpoint, Glucocorticoid-Free Remission